Your CSV is on the way
We’ve sent your CSV file to [email protected]
Claimed by
owner Add to list
Fore Biotherapeutics
Former names: NovellusDx
Precision Oncology Treatments
Stealth Mode
Fore Biotherapeutics
Fore Biotherapeutics Overview
Cumulative Funding Raised Over Time ($)
Employees Over Time
Fore Biotherapeutics Climate Tech relevance
undefined
No Data, yet.
Sorry, no content found under this section.
Aug 22, 2023
www.businesswire.com
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
undefined
Apr 26, 2023
www.businesswire.com
FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
undefined
Mar 20, 2023
www.businesswire.com
FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies
undefined
Feb 23, 2023
www.businesswire.com
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors
undefined
Sep 28, 2022
www.galvnews.com
Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations
undefined
Aug 9, 2022
www.businesswire.com
Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022
undefined
Apr 18, 2022
www.businesswire.com
Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer
undefined
Mar 1, 2021
www.calcalistech.com
ForeBio is on its way to Nasdaq at a $500 million valuation
#Public Trading #Investment
Feb 22, 2021
endpts.com
A diagnostics company completes its pharma makeover, rebranding as Fore with Immunomedics vet at the helm
#Acquisition
Feb 22, 2021
www.businesswire.com
NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board
undefined
Nov 23, 2020
www.businesswire.com
Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment
undefined
Sep 21, 2020
www.businesswire.com
Novellus Closes $57M Series C Financing
undefined
Jun 3, 2020
www.fiercebiotech.com
Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon
undefined
Oct 25, 2019
www.genomeweb.com
Cancer Genetics Settles Failed Merger Deal With NovellusDx;Receives $6M From Interpace
#Acquisition #Investment #Management Changes
Apr 18, 2019
news.christianacare.org
The Gene Editing Institute licenses CRISPR technology to NovellusDx to drive next-generation cancer care - ChristianaCare News
#Partners
Sep 18, 2018
globenewswire.com
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge
#Acquisition
Apr 30, 2018
www.globes.co.il
Israeli cancer profiling co NovellusDx raises $6m
#Investment
Jun 21, 2017
www.prnewswire.com
NovellusDx Announced Today the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
#Partners
Mar 1, 2017
www.newswise.com
Personalized Cancer Therapy on the Horizon Thanks to New Genomic Cancer Research Partnership
#Partners
Jun 22, 2016
www.globes.co.il
OrbiMed invests $2.5m in cancer profiling co NovellusDx
#Investment #Expand
Dec 24, 2015
www.globes.co.il
Israeli cancer profiling co NovellusDx raises $10m
#Investment
Similar Companies
Driven by Finder AI
related content
Lists. Maps. Reports
Team Members
undefined
Connect with team members
Affiliated Organizations
(undefined)Web & social links
https://fore.bio
Locations
Israel
Offices Abroad
Photos & videos
(0)No Data, yet.
Sorry, no content found under this section.
Fore Biotherapeutics Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
Private Equity Funding
D Round
$75M
Aug 2023
8
Investors
$75M
Lead
Medicxi
Foreign VC and Private Equity
United Kingdom
Lead
SR One
Foreign Corporate VC
Follow on
United Kingdom
Samsung Venture Investment
Foreign Corporate VC
South Korea
OrbiMed
Foreign VC and Private Equity
Follow on
United States
Cormorant Asset Management
Foreign Institutional Investor
Follow on
United States
HBM Healthcare Investments
Foreign VC and Private Equity
Follow on
Switzerland
Wellington Partners
Foreign VC and Private Equity
Germany
Novartis Venture Fund
Foreign VC and Private Equity
Follow on
Switzerland
C Round
$57M
Sep 2020
7
Investors
$57M
Lead
Pontifax
Israeli VC and Private Equity
Follow on
Israel
HBM Healthcare Investments
Foreign VC and Private Equity
Switzerland
Cormorant Asset Management
Foreign Institutional Investor
United States
SR One
Foreign Corporate VC
United Kingdom
Wellington Management
Foreign Other
United States
Novartis Venture Fund
Foreign VC and Private Equity
Switzerland
OrbiMed
Foreign VC and Private Equity
Follow on
United States
B Round
$12.5M
Jun 2016
2
Investors
$12.5M
A Round
$2M
Dec 2015
1
Investors
$2M
Seed
$2M
Jul 2013
0
Investors
$2M
Non-Equity Funding
Grant
$5M
Aug 2017
0
Grantors
$5M
Mergers and Acquisitions
Fore Biotherapeutics Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
D Round
$75M
Aug 2023
8
Investors
$75M
Lead
Medicxi
Foreign VC and Private Equity
United Kingdom
Lead
SR One
Foreign Corporate VC
Follow on
United Kingdom
Samsung Venture Investment
Foreign Corporate VC
South Korea
OrbiMed
Foreign VC and Private Equity
Follow on
United States
Cormorant Asset Management
Foreign Institutional Investor
Follow on
United States
HBM Healthcare Investments
Foreign VC and Private Equity
Follow on
Switzerland
Wellington Partners
Foreign VC and Private Equity
Germany
Novartis Venture Fund
Foreign VC and Private Equity
Follow on
Switzerland
C Round
$57M
Sep 2020
7
Investors
$57M
Lead
Pontifax
Israeli VC and Private Equity
Follow on
Israel
HBM Healthcare Investments
Foreign VC and Private Equity
Switzerland
Cormorant Asset Management
Foreign Institutional Investor
United States
SR One
Foreign Corporate VC
United Kingdom
Wellington Management
Foreign Other
United States
Novartis Venture Fund
Foreign VC and Private Equity
Switzerland
OrbiMed
Foreign VC and Private Equity
Follow on
United States
Grant
$5M
Aug 2017
0
Investors
$5M
B Round
$12.5M
Jun 2016
2
Investors
$12.5M
A Round
$2M
Dec 2015
1
Investors
$2M
Seed
$2M
Jul 2013
0
Investors
$2M
Fore Biotherapeutics News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Aug 22, 2023
www.businesswire.com
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
undefined
Apr 26, 2023
www.businesswire.com
FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
undefined
Mar 20, 2023
www.businesswire.com
FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies
undefined
Feb 23, 2023
www.businesswire.com
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors
undefined
Sep 28, 2022
www.galvnews.com
Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations
undefined
Aug 9, 2022
www.businesswire.com
Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022
undefined
Apr 18, 2022
www.businesswire.com
Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer
undefined
Mar 1, 2021
www.calcalistech.com
ForeBio is on its way to Nasdaq at a $500 million valuation
#Public Trading #Investment
Feb 22, 2021
endpts.com
A diagnostics company completes its pharma makeover, rebranding as Fore with Immunomedics vet at the helm
#Acquisition
Feb 22, 2021
www.businesswire.com
NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board
undefined
Nov 23, 2020
www.businesswire.com
Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment
undefined
Sep 21, 2020
www.businesswire.com
Novellus Closes $57M Series C Financing
undefined
Jun 3, 2020
www.fiercebiotech.com
Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon
undefined
Oct 25, 2019
www.genomeweb.com
Cancer Genetics Settles Failed Merger Deal With NovellusDx;Receives $6M From Interpace
#Acquisition #Investment #Management Changes
Apr 18, 2019
news.christianacare.org
The Gene Editing Institute licenses CRISPR technology to NovellusDx to drive next-generation cancer care - ChristianaCare News
#Partners
Sep 18, 2018
globenewswire.com
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge
#Acquisition
Apr 30, 2018
www.globes.co.il
Israeli cancer profiling co NovellusDx raises $6m
#Investment
Jun 21, 2017
www.prnewswire.com
NovellusDx Announced Today the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
#Partners
Mar 1, 2017
www.newswise.com
Personalized Cancer Therapy on the Horizon Thanks to New Genomic Cancer Research Partnership
#Partners
Jun 22, 2016
www.globes.co.il
OrbiMed invests $2.5m in cancer profiling co NovellusDx
#Investment #Expand
Dec 24, 2015
www.globes.co.il
Israeli cancer profiling co NovellusDx raises $10m
#Investment
Related Content
Fore Biotherapeutics Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Similar Companies
Driven by Finder AI
Fore Biotherapeutics Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,
